OTC: HNSBF - Hansa Biopharma AB (publ)

Rentabilité sur six mois: 0%
Secteur: Healthcare

Calendrier des promotions Hansa Biopharma AB (publ)

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

Plus de détails
The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Цена ао 2.93
Выручка 0.0315
EBITDA -3.3
Число акций ао 0.05254 млрд
P/S 108.14
P/BV 0.6464
EV/EBITDA -0.544
Сайт https://www.hansabiopharma.com
Валюта usd
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: 0% (2.93)
Changement de prix par semaine: 0% (2.93)
Changement de prix par mois: 0% (2.93)
Changement de prix sur 3 mois: 0% (2.93)
Changement de prix sur six mois: 0% (2.93)
Changement de prix par an: -2.33% (3)
Evolution du prix sur 3 ans: -83.9% (18.2)
Evolution du prix sur 5 ans: -36.3% (4.6)
Evolution des prix depuis le début de l'année: -2.33% (3)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 8.84 1
P/BV -0.7013 0
P/E 0 0
EV/EBITDA -3.26 0
Total: 3.5

Efficacité

Nom Signification Grade
ROA, % -8.11 0
ROE, % 49.19 10
Total: 3.33

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -11 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 344.83 10
Rentabilité Ebitda, % -74.96 0
Rentabilité EPS, % -80.1 0
Total: 4
Plus de détails

Établissements Volume Partager, %
SPDR Portfolio Developed World ex-US ETF 115184 0.22
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 30740 0.06
SPDR (R) Portfolio Europe ETF 611 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Søren Tulstrup M.Sc President & CEO 16.12M 1965 (59 années)
Dr. Christian Kjellman Senior VP & COO N/A 1967 (57 années)
Dr. Hitto Kaufmann Ph.D. Chief Scientific Officer N/A 1971 (53 année)
Ms. Eva-Maria Joed Vice President of Finance & Administration N/A 1969 (55 années)
Mr. Klaus Sindahl VP & Head of Investor Relations N/A
Ms. Anne Säfström Lanner Senior VP & Chief Human Resources Officer N/A 1969 (55 années)
Mr. Emanuel Björne VP & Head of Business Development N/A 1973 (51 année)
Dr. Lena Winstedt Head of Science N/A 1969 (55 années)
Ms. Vincenza Nigro M.B.A. VP & Head of Medical Affairs N/A
Mr. C. Evan Ballantyne Chief Financial Officer N/A 1960 (64 année)

Adresse: Sweden, Lund, ScheelevAegen 22 - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.hansabiopharma.com